Syncona Share Discussion Threads

[brexitplus] 26/4/2019 07:40

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it will deliver two oral and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting being held from 29th April to 2nd May, 2019 in Washington D.C.
Freeline will present information on their differentiated AAV manufacturing platform and analytical capabilities, leveraged by more than 20 years of AAV experience across the CMC team. The abstracts demonstrate the novelty and built-in quality of the Freeline manufacturing platform. The Freeline approach includes a proprietary plasmid packaging system in combination with adherent culture in the iCELLis® bioreactor platform. This enables Freeline to produce safe, potent and high-quality product at commercial scale. Freeline will also present information on its state-of-the-art analytical methods used for in-depth product characterization to further drive improvements in product quality and safety.

“We are proud to present updates on our CMC and analytics platform at ASGCT,” commented Markus Hörer, Chief Technology Officer of Freeline. “Our presentations demonstrate how our novel approaches to each step of the AAV production process, from vector design to cassette optimisation to adherent mammalian bioprocessing, have enabled us to reach commercial quality and scale with our platform. Our platform is deployed for all of our programs including our research pipeline and ensures fast progression with high quality products through all development stages.”

[brexitplus] 26/4/2019 07:05

WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”;).

[brexitplus] 24/4/2019 15:08

Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced upcoming presentations at the American Urological Association’s 2019 Annual Meeting, AUA2019, being held May 3 - 6, 2019, in Chicago, Ill. Presentations on Axumin® (fluciclovine F 18) Injection include additional analyses from the LOCATE clinical trial (NCT02680041), a prospective, U.S., multicenter, open-label study investigating the impact of 18F fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer after initial prostate cancer treatment and negative or equivocal findings on standard-of-care imaging.

[brexitplus] 17/4/2019 07:54

I’m not sure anything is planned until the prelims in June. Syncona used to froduce a monthly factsheet which seems to have been discontinued.

[graygray1] 17/4/2019 05:20

When will end March NAV be revealed?

[luxaeterna1] 16/4/2019 14:15

Does anyone have a practical estimate of Blue Earth's revenue? It's currently around £80mpa and it has doubled in the last year. 5 year outlook ~ £300mpa revenue perhaps?

[brexitplus] 16/4/2019 10:27

Blue Earth announcement

Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual circumstances of patients. These updated EAU PCa Guidelines state that “18F – Fluciclovine has been approved in the US and Europe, and therefore is currently the only PCa-specific radiotracer widely commercially available.”

[luxaeterna1] 16/4/2019 08:56

Nice tick up this morning?

[ltinvestor] 12/4/2019 08:35

Nightstar raised at $18 and drifted down to $10 before being bought out 3 months later for $25.5.

[luxaeterna1] 11/4/2019 13:21

Depends how you look at things. Autolus has been trading in a $24-32 price range, they just raised equity (i.e. sold new shares on the market) at $24 per share. Some investors are long-term, others will sell anything for a quick profit. This becomes a self-fulfilling prophecy at times, so when new equity is raised at (for example) $24, the price will trend towards $24, because there is a trader on the market who could sell their new stock for profit at any value above $24, while others may sell stock or go short towards the new price @ $24, in expectation of a drop.

I wish the market did not work like this, but it does!

[graygray1] 11/4/2019 13:00

Sounds plausible but if so why has Autolus dropped so much in the last couple of days? Is this some impact from the IPO announcement? Surely that should be beneficial?

[luxaeterna1] 11/4/2019 12:27

Autolus now have a $300m warchest - that's serious cash. I can't believe they need all that for R&D, are they highly confident and gearing up for multiple new production lines?

[brexitplus] 11/4/2019 07:20

Lots of news today. Gyroscope and Orbit tie up a good move in my opinion. Autolus fund raising shows confidence.

[luxaeterna1] 10/4/2019 15:27

There's a new Syncona presentation on their website (from last week).

[ltinvestor] 08/4/2019 19:31

5 from 7 patients still in remission after 5 months.Better than decent, imo

[luxaeterna1] 08/4/2019 10:19

I think they were decent enough. It's a good slog now through to Q3 2019 for the bigger set of results, Autolus seem happy enough that there is efficacy at some levels, its now down to proving that efficacy and safety profile, to figure out what the best treatment plans are and for what patient populations.

[ltinvestor] 01/4/2019 08:25

Did I misread those Autolus results on Friday evening??

[ltinvestor] 29/3/2019 21:42

AUTO1 results statement in adult trial released after Nasdaq closed last night show excellent early remission rates and CAR expansion/ persistence...,Exciting technology showing positive results

[graygray1] 29/3/2019 04:42

I think there will be a new NAV shortly. Presume this will be higher after recent events.

[ltinvestor] 28/3/2019 22:44

Autolus ended up another 9% !!

[ltinvestor] 28/3/2019 16:40

176,000 buy at £2.58

[graygray1] 28/3/2019 10:04

Seems like Autolus results were good but not spectacular. Still early days I guess. Good to see SYNC getting away from those recent lows.

[ltinvestor] 28/3/2019 07:40

Autolus up another 5% on Nasdaq...

[luxaeterna1] 27/3/2019 10:58

The Autolus presentation from yesterday